证券研究报告 | 2025年10月10日 利民股份（002734.SZ） 优于大市 多个主营产品量价齐升，代森锰锌在巴西获原药及制剂登记 公司发布 2025 年前三季度业绩预告，业绩实现同比大幅增长。预计 2025 年 前三季度实现归母净利润3.84 亿元-3.94 亿元，同比增长649.71%-669.25%； 其中第三季度预计实现归母净利润 1.15 亿元-1.25 亿元，同比增长 490.85%-542.23%，环比下降 22.36%-28.57%。公司业绩大幅增长的主要原因 是公司主要产品销量和价格同比上涨、毛利率提升以及参股公司业绩上涨带 来投资收益增加。 核心产品景气度持续向好，盈利能力增强。据百川盈孚，2024 年 3 月中旬至 今，甲维盐和阿维菌素市场价格分别从 50、35 万元/吨上涨至 65、45.5 万 元/吨；2025 年 3 月以来，代森锰锌的市场价格从 2.35 万元/吨上涨至 2.75 万元/吨；百菌清市场价格已从 2024 年 1 月的 1.8 万元/吨上涨至 2025 年 10 月的 2.95 万元/吨；2025 年 7 月 4 日国内酒石酸泰乐菌素市场主流成交参考 价 29 ...

10月9日晚间，利民股份（002734）公告，预计2025年前三季度净利润为3.84亿元—3.94亿元，比上年同 期增长649.71%—669.25%；扣非净利润3.7亿元—3.81亿元，同比增长994.97%—1026.92%。 其中今年第三季度，利民股份预计净利润为1.15亿元—1.25亿元，同比增长490.85%—542.23%；扣非净 利润1.13亿元—1.24亿元，同比增长1993.39%—2192.79%。 利民股份表示，报告期内公司主要产品销量和价格同比上涨，毛利率提升，同时参股公司业绩增长带动 投资收益增加，推动盈利大幅上升。 利民股份的杀菌剂产品主要包括代森类、百菌清、霜脲氰、三乙膦酸铝、嘧霉胺、威百亩、嘧菌酯等原 药及制剂；杀虫剂产品包括阿维菌素、甲氨基阿维菌素苯甲酸盐、噻虫啉、吡蚜酮、噻虫胺、噻唑膦、 呋虫胺、除虫脲、多杀霉素等原药和多种单剂及复配制剂；除草剂产品主要包括草铵膦、精草铵膦、硝 磺草酮、环磺酮等原药及制剂；兽药产品主要包括伊维菌素、乙酰氨基阿维菌素、泰妙菌素、沃尼妙林 等原药和制剂产品。 今年上半年，利民股份实现营业收入24.52亿元，同比增长6.69%；净利润2.69亿元 ...

Core Viewpoint - The article highlights how regulatory challenges and innovative solutions can reshape the business landscape for companies, specifically focusing on Nantong Taihe Chemical Co., Ltd. and its efforts to enter the semiconductor application market with a new environmentally friendly product [1][2]. Group 1: Company Overview - Nantong Taihe Chemical Co., Ltd. is the first company in Nantong to be listed on the Growth Enterprise Market this year, with core products like Bacillus thuringiensis and Pyraclostrobin being industry benchmarks [2]. - The company aims to leverage its production capacity to produce "electronic-grade carbonyl sulfide," a more environmentally friendly alternative to traditional specialty gases [2]. Group 2: Regulatory Challenges - The company faced significant hurdles due to the requirement of holding over 100 specialized gas cylinders to obtain the necessary permits, with each cylinder costing 51,000 yuan and a long production cycle [2]. - The initial investment required to meet this regulatory requirement was over 5 million yuan, which would lead to idle capacity and disrupt the product launch schedule [2]. Group 3: Innovative Solutions - A breakthrough occurred when the local market supervision bureau identified a regulatory loophole that allowed the company to apply for permits with only 20 gas cylinders as an initial configuration, with plans to gradually increase the number based on market demand [3]. - This innovative approach not only alleviated the financial burden on the company, saving over 4 million yuan in initial investments, but also expedited the entry of the new product into the semiconductor market [4]. Group 4: Impact and Future Directions - The successful implementation of this regulatory adjustment serves as a model for similar projects nationwide, promoting a more flexible and supportive regulatory environment [4]. - The local government's shift from rigid enforcement to proactive support reflects a broader change in service philosophy, aiming to better understand and meet the needs of businesses [4].

Industry Research Summary - Pesticide Industry Industry Overview - The global pesticide market is approximately $70 billion, highly concentrated with multinational companies such as Syngenta, FMC, Bayer, Corteva, and BASF dominating the market, providing integrated services of seeds, fertilizers, and pesticides [1][2] - The domestic pesticide market in China is fragmented, influenced by historical factors and the participation of both domestic and foreign enterprises. About 70% of raw material exports are for international markets, while 30% are for domestic sales [1][4] Market Dynamics - In 2021, a significant increase in demand occurred due to inventory replenishment, but prices began to decline from Q4 2022, leading to a bottoming out phase in 2024 and 2025 [1][5] - Key products expected to perform well in 2025 include Bacillus subtilis, Mancozeb, Abamectin, Methomyl, and Acetochlor, driven by factors such as disease outbreaks and supply shortages [1][6] Supply and Demand Analysis - Glyphosate has a global supply of approximately 1.2 million tons, with China supplying 800,000 tons and Monsanto accounting for 370,000-380,000 tons. The global demand is around 900,000 tons, with a capacity utilization rate of about 75% [1][9] - The price of glyphosate has increased from 23,000 yuan to 27,000 yuan per ton due to reduced supply and declining inventory, leading to improved profitability for companies [1][9] Product-Specific Insights - Glyphosate's future outlook is optimistic due to stable supply-demand dynamics and no new capacity additions allowed by policy [1][8] - In contrast, Glufosinate has faced oversupply issues since being listed in a restricted directory in 2024, with demand growth lagging behind supply growth, resulting in poor price and margin performance [1][10][11] Company-Specific Strategies - Yangnong Chemical's investment logic is based on capacity expansion and price elasticity opportunities, while Limin Co. focuses on reversing its main business challenges and developing innovative products [1][13] - Guangxin's core competitiveness lies in its comprehensive layout along the phosgene industrial chain, enabling it to achieve the lowest cost operations [1][15] - Runfeng Company emphasizes global formulation channel development, achieving periodic growth through continuous registration and channel establishment [1][16] Key Considerations for Industry Analysis - Important factors to monitor include cyclical trends, supply-demand relationships, the development of innovative products, and the characteristics of the formulation industry, which is asset-light and high-turnover [1][17] - Tracking inventory can be done through multinational company financial reports, communication with listed companies, and industry exhibitions [1][12]

Core Viewpoint - Taihe Chemical's 2025 semi-annual report indicates significant growth in both revenue and net profit, driven by core product competitiveness and successful international and green manufacturing strategies [1] Group 1: Performance Highlights - For the first half of 2025, Taihe Chemical achieved a revenue of 2.413 billion yuan, a year-on-year increase of 23.15% [2] - The net profit attributable to shareholders reached 182 million yuan, a substantial year-on-year growth of 72.20% [2] - The basic earnings per share were 0.43 yuan, reflecting a year-on-year increase of 65.38% [2] - The company reported a net cash flow from operating activities of 171 million yuan, a significant improvement of 198.90% year-on-year [2] - Total assets as of June 30, 2025, were 6.228 billion yuan, an increase of 11.45% from the end of the previous year [2] Group 2: Product and Innovation - Taihe Chemical maintains a leading position in key products such as Bacillus thuringiensis, pyraclostrobin, and 2,4-D, with production scale and technology at an internationally advanced level [3] - R&D expenses increased by 47.07% year-on-year, focusing on outsourced research and talent acquisition [3] - The company’s new insecticide "cyprodinil" has received partial international registration, marking a shift from imitation to a combination of imitation and innovation [3] Group 3: Sustainability and Internationalization - The company is committed to green manufacturing, implementing advanced environmental technologies for efficient waste management [3] - Taihe Chemical has established a sales network covering North America, South America, Southeast Asia, and Europe, collaborating with major international agricultural chemical companies [3] - The company aims to enhance its global market penetration and brand influence through increased investment in overseas registration and localization of formulation business [3] Group 4: Strategic Outlook - Despite facing geopolitical risks, currency fluctuations, and industry competition, the company plans to continue focusing on R&D innovation, green manufacturing, and international expansion [4] - The global pesticide market is normalizing, and the rigid demand for pesticides under food security strategies is expected to support the company's market share expansion during the industry recovery cycle [4] - Analysts highlight that Taihe Chemical is signaling strong growth potential and confidence in its future through solid performance and clear strategic direction [4]

Group 1 - The core viewpoint of the articles highlights the strong financial performance of Nantong Taihe Chemical Co., Ltd. in the first half of 2025, with a revenue of 2.413 billion yuan, representing a year-on-year growth of 23.15%, and a net profit of 182 million yuan, up 72.20% [1] - The company specializes in the research, production, and sales of pesticide products and functional chemicals, holding a leading position in the industry with its core products including Bacillus subtilis, pyraclostrobin, and 2,4-D [1] - The company's main products, fungicides and herbicides, showed impressive performance in the first half of the year, with fungicide revenue reaching 900 million yuan, a year-on-year increase of 37.98%, and herbicide revenue at 1.041 billion yuan, up 16.96% [1] Group 2 - The newly developed product, cyhalofop-butyl, has been recognized by the International Resistance Action Committee (IRAC) as part of Group 30, becoming the fourth insecticide to enter this group, and has obtained some foreign registration certificates, with domestic registration in the public announcement stage [2] - The company is actively pursuing strategic acquisitions to further expand its formulation business, with a recent announcement to acquire the remaining 51% stake in Guangdong Haode Crop Technology Co., Ltd. for 22.083 million yuan, which will enhance the company's upstream and downstream integration and broaden its business segments [2]

Core Insights - The company reported a revenue of 2.413 billion yuan for the first half of 2025, representing a year-on-year growth of 23.15%, and a net profit attributable to shareholders of 182 million yuan, up 72.20% year-on-year, indicating a robust growth trend [1] - The net cash flow from operating activities turned positive, reaching 171 million yuan, with a significant year-on-year increase of 198.90% [1] - In Q2 2025, the company achieved a revenue of 1.38 billion yuan, reflecting a quarter-on-quarter growth of 33.69% [1] R&D Investment and Innovation - The company increased its R&D investment to 89.7354 million yuan in the first half of 2025, a year-on-year increase of 47.07% [2] - The focus of R&D is on core process breakthroughs, establishing a technology innovation system centered on ammonia oxidation, chlorination, and hydrogenation, which supports its leading position in key products [2] - The company is transitioning from traditional imitation to a combination of imitation and innovation, launching new products like cyclopropyl insecticide, which has been recognized by the International Resistance Action Committee [2] Overseas Market Expansion - The company has established a sales network covering major agricultural markets globally and formed stable partnerships with renowned international firms [3] - A project is planned in Egypt to enhance the company's global market share and improve overseas delivery efficiency [3] - The company aims to leverage technological innovation to deepen its global market presence and contribute to food security and sustainable agricultural development [3]

Group 1: Limin Co., Ltd. - In the first half of 2025, Limin Co., Ltd. reported sales revenue of 2.452 billion yuan, a year-on-year increase of 6.69% [1] - The net profit reached 269 million yuan, showing a significant year-on-year growth of 747.13% [1] - The performance improvement is attributed to the increase in both volume and price of core products, cost reduction, overseas market expansion, and enhanced capacity utilization [1] - The company has a strong order book for Manganese Zinc orders and minimal inventory, with robust demand for Bacillus thuringiensis in Brazil [1] - The 'one certificate, one product' policy is favorable for the company, and there are plans for technological upgrades and brand building in the second half of the year [1] Group 2: Xinzhi Group - Xinzhi Group achieved revenue of 2.86 billion yuan in the first half of 2025, with a net profit of 50 million yuan [2] - The net profit margin for the second quarter improved to 2.7%, with a quarter-on-quarter growth of 677% [2] - The gross profit margin for the first half was 10.84%, an increase of 0.64 percentage points year-on-year [2] - The drone business is experiencing rapid growth, primarily supplying DJI with motor products for various types of drones [2] - The company is focusing on enhancing product quality in traditional businesses and shortening development cycles in emerging sectors through collaborative R&D [2] Group 3: *ST Chengchang - The company has seen a significant increase in orders and projects due to recovering downstream user demand [3] - Some remote sensing satellite projects are expected to enter small batch production in 2024 and mass production in 2025, indicating substantial growth potential [3] - The company maintains a stable gross profit margin by improving R&D efficiency and optimizing production processes [3] - There is a technological advantage in the low Earth orbit satellite sector, which is anticipated to become a new growth point [3] - The company is actively expanding applications in low-altitude economies and addressing detection blind spots [3]

Core Viewpoint - Limin Co., Ltd. achieved a net profit attributable to shareholders of 269 million yuan in the first half of the year, representing a year-on-year increase of 747.13% [1] Financial Performance - In Q2, the company realized a net profit attributable to shareholders of 161 million yuan, showing a year-on-year growth of 299.54% and a quarter-on-quarter increase of 48.66% [1] - The company's performance for the first half of 2025 is expected to continue growing at a rate of 747% year-on-year [1] Market Position and Strategy - The company has further solidified its position as a leading domestic pesticide manufacturer, focusing on technological innovation, global expansion, and green transformation [1] - There has been a continuous increase in market share, with major product prices and sales volumes rising year-on-year, alongside an improvement in gross profit margins [1] Research and Development - The company's technical research and development capabilities have been steadily enhanced, with progress in the chemical synthesis creation plan and successful collaboration with BASF on innovative drug development [1] - Product planning is being systematically developed, with improvements in formulation research and solid advancements in biological synthesis research [1] Market Outlook - The second half of the year marks the peak sales season in the South American market, with expected strong demand for fungicide products such as mancozeb and chlorothalonil, which will support continued market growth [1]

Financial Performance - In the first half of 2025, the company achieved a sales revenue of CNY 2.452 billion, a year-on-year increase of 6.69% [3] - Net profit reached CNY 269 million, reflecting a significant year-on-year growth of 747.13% [3] - The gross profit margin was 26.13%, up by 8.11% compared to the previous year [3] - Accounts receivable decreased by 8.01% to CNY 599 million [3] - The debt-to-asset ratio improved to 47.78%, down by 11.75% year-on-year [3] Key Drivers of Performance - Core products saw both volume and price increases, with strong market demand for key products such as Mancozeb, Chlorothalonil, Abamectin, and Methomyl [3] - The "Safety Cushion Resilience Plan" effectively controlled costs and improved efficiency through optimized production processes and supply chain management [4] - Successful expansion into overseas markets, particularly in Brazil, where the company obtained several product registrations [4] - Enhanced capacity utilization and operational efficiency due to improved market conditions and internal management [4] Product Contribution - The agricultural pesticide segment generated CNY 2.199 billion in revenue, a 4.63% increase year-on-year, with a gross margin of 26.45% [6] - The veterinary medicine segment reported revenue of CNY 229 million, a growth of 27.73% year-on-year, with a gross margin of 21.66% [6] - Specific product performance included: - Agricultural fungicides: CNY 1.240 billion in revenue, gross margin of 33.77% [6] - Agricultural insecticides: CNY 748 million in revenue, gross margin of 24.32% [6] - Agricultural herbicides: CNY 208 million in revenue, with a decrease in gross margin by 7.47% [6] Investment and Market Outlook - Investment income increased significantly, primarily from the investment in Jiangsu Xinhai Agricultural Chemical Co., Ltd. [7] - The price of Mancozeb has risen approximately 20% since January 2025, with strong demand in Brazil, where the product is crucial for soybean disease management [8] - The company expects continued growth in demand for Mancozeb, with import volumes in Brazil nearly doubling in 2024 to 88,000 tons [8] Strategic Initiatives - The company is focusing on enhancing brand influence and expanding overseas operations, with significant revenue from Brazil (CNY 200 million) and the U.S. (over CNY 70 million) in the first half of 2025 [11] - The implementation of the "One Certificate, One Product" policy is anticipated to benefit the company due to its extensive registration resources [12] - Future plans include improving production quality, expanding market presence, and enhancing technological innovation [18]